AbbVie to Deploy Adaptive’s clonoSEQ Assay to Assess MRD Status Across Multiple Myeloma Studies

 AbbVie to Deploy Adaptive’s clonoSEQ Assay to Assess MRD Status Across Multiple Myeloma Studies

AbbVie to Deploy Adaptive’s clonoSEQ Assay to Assess MRD Status Across Multiple Myeloma Studies

Shots:

  • AbbVie in collaboration with Adaptive evaluate depth and duration of response to venetoclax and measure minimal residual disease (MRD) status in MM treated patients utilizing Adaptive’s next-generation sequencing (NGS)-based clonoSEQ assay
  • The partnership encourages the development & regulatory approval of venetoclax in MM and the increasing use of clonoSEQ in drug development as a method to assess response to new therapies
  • Venetoclax is a first-in-class small molecule selective BCL-2 inhibitor being evaluated in studies for MM patients while clonoSEQ is the first and only FDA authorized MRD test to monitor MRD in MM and B-cell ALL using DNA from bone marrow samples

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post